Dr. Pavic on masitinib plus docetaxel in first-line mCRPC

“What we found was the [progression-free survival] value was improved in the subgroup of patients with low [alkaline phosphatase levels],” says Michel Pavic, MD.

Body: In this video, Michel Pavic, MD, discusses the background and findings of the study, “Masitinib plus docetaxel as first-line treatment of metastatic castrate refractory prostate cancer: results from study AB12003,” presented recently at the 2021 American Urological Association Annual Meeting. Pavic is an oncologist and head of the hematology-oncology service at CIUSSS de l’Estrie (CHUS) and a professor of medicine and health sciences at the University of Sherbrooke, Quebec, Canada.